Exelixis, Inc. — Form 10-K Summary
Reporting period: Fiscal 2014, ended January 2, 2015 (a 53-week year); comparative fiscal 2013 ended December 27, 2013. Although the request metadata refers to 2013 Q4, this filing reports fiscal 2014 annual results. Financial figures below are in U.S. dollars.
Business context
Exelixis is a cancer-focused biopharmaceutical company. Its principal wholly owned asset is cabozantinib, marketed as COMETRIQ for progressive, metastatic medullary thyroid cancer (MTC) in the United States and, conditionally, the European Union. The company’s other leading asset, cobimetinib, is partnered with Genentech. Exelixis concentrated development spending primarily on cabozantinib and reported more than 45 cabozantinib clinical trials, including Phase 3 studies in metastatic renal cell carcinoma (mRCC) and advanced hepatocellular carcinoma (HCC).
Key financial results and position
| Metric | FY2014 | FY2013 |
|---|---|---|
| Total revenue | $25.1 million | $31.3 million |
| Net product revenue | $25.1 million | $15.0 million |
| Operating expenses | $249.6 million | $232.1 million |
| Research and development | $189.1 million | $178.8 million |
| Selling, general and administrative | $50.8 million | $51.0 million |
| Operating loss | $224.5 million | $200.7 million |
| Net loss | $268.5 million | $244.8 million |
| Net loss per share, diluted | $1.38 | $1.33 |
| Operating cash used | $235.4 million | $198.8 million |
- Net revenue declined 20% as increased COMETRIQ sales were more than offset by the absence of collaboration and milestone revenue recognized in 2013. Product revenue rose approximately 67% year over year.
- Reported product gross margin was 92%, compared with 93% in 2013. The filing cautions that early-launch margins may not represent future margins.
- Cash, cash equivalents and investments totaled $242.8 million at year-end, down from $415.9 million. Of this, $144.3 million was identified as available for operations; other amounts included restricted funds and $81.6 million of compensating-balance investments required under the Silicon Valley Bank facility.
- Working capital was negative $4.6 million, versus positive $178.8 million a year earlier. Total assets were $328.0 million, total liabilities $442.8 million, and stockholders’ deficit $114.8 million.
- Debt carrying value was $361.7 million, including $98.9 million current convertible notes, $182.4 million long-term 2019 Notes and $80.4 million under the Silicon Valley Bank facility. The Deerfield Notes had $104.0 million principal outstanding; the filing expected the company to exercise an extension option for $100.0 million of principal to July 2018. The 2019 Notes have $287.5 million principal and mature in 2019.
Material developments and outlook
- Cabozantinib in MTC: The pivotal EXAM study showed median progression-free survival of 11.2 months versus 4.0 months on placebo. Final overall-survival analysis did not show a statistically significant difference overall. A positive survival result in the RET M918T subgroup was exploratory and not adjusted for multiple testing.
- Cabozantinib in mCRPC: Phase 3 COMET-1 did not meet its overall-survival primary endpoint, and COMET-2 did not meet its pain-response primary endpoint. Exelixis terminated cabozantinib development in mCRPC and halted other company-sponsored studies in that setting.
- Next cabozantinib catalysts: METEOR, the Phase 3 mRCC trial, completed target enrollment; top-line data were expected in the second quarter of 2015. CELESTIAL, the Phase 3 advanced-HCC trial, was expected to report top-line results in 2017.
- Cobimetinib: In the Genentech-led coBRIM melanoma trial, the combination with vemurafenib improved investigator-assessed median progression-free survival to 9.9 months from 6.2 months. The U.S. NDA received priority review, with an FDA action date of August 11, 2015. Exelixis is entitled to a tiered U.S. profit share and low double-digit ex-U.S. royalties, but must share U.S. commercialization costs.
- Cost reduction: A restructuring begun in September 2014 targeted a workforce of approximately 80 employees. Exelixis recorded $7.6 million in total restructuring charges in FY2014, including $6.1 million for the 2014 plan, and anticipated further facility and other restructuring costs.
- Liquidity outlook: Management expected available operating cash, short-term investments and product revenue to fund operations through at least December 31, 2015, assuming cost savings and the anticipated Deerfield extension. Management said longer-term operations depended substantially on COMETRIQ and cobimetinib commercial success and could require additional financing, further cuts, asset sales or reduced development activity.
Risks, contingencies and unusual items
- The company had a history of substantial losses and negative operating cash flow; it expected both to continue. FY2014 net loss was $268.5 million and accumulated deficit was $1.8 billion.
- Revenue was highly concentrated: 99% of FY2014 revenue came from Diplomat Specialty Pharmacy. The commercial business also relied on third parties for manufacturing, logistics, dispensing and European distribution.
- Liquidity and debt risks include the near-term Deerfield maturity absent extension, debt covenants and collateral requirements, substantial interest expense, and potential dilution from equity issuance or debt conversion.
- Clinical and regulatory outcomes remain uncertain. COMET-1 and COMET-2 failures illustrate trial risk; the ongoing mRCC and HCC trials could fail, be delayed or yield results insufficient for approval.
- COMETRIQ carries boxed warnings for gastrointestinal perforations and fistulas and severe hemorrhage, as well as other significant safety precautions. Post-marketing studies and nonclinical requirements remain relevant.
- FY2014 included a $2.3 million European distributor project-management fee recorded as a reduction of revenue, $48.6 million of interest expense, and a $1.8 million noncash gain from revaluing Deerfield warrants. The filing reported no material legal proceedings or material off-balance-sheet arrangements.
Most important facts for investors to verify
- Whether the Deerfield extension was exercised on the disclosed terms, and the resulting interest, cash-payment and dilution implications.
- METEOR and CELESTIAL results, subsequent regulatory filings, and the company’s ability to fund trials through those milestones.
- COMETRIQ sales growth, net pricing and rebates, and the impact of reliance on a single U.S. specialty pharmacy.
- The FDA’s decision on cobimetinib and the actual economics of Exelixis’s U.S. profit-and-cost share and ex-U.S. royalties.
- Cash available for operations after restricted and collateral balances, operating cash burn, and progress in achieving restructuring savings.
- Debt principal and carrying amounts, covenant compliance, and potential share dilution from convertible notes, warrants and equity compensation.